To investigate the relevance of concomitant BRAF and KIT/PDGFRA mutations in primary and secondary resistance to Imatinib, we conducted a molecular study of the hot spots of KIT, PDGFRA and BRAF. Only one case out of the 407 analyzed GIST carried the BRAF V600E mutation. This evidence concerns the gene BRAF and gastrointestinal stromal tumor.